memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Latest congress reports


Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.



    memo – inOncology SPECIAL ISSUE

    Congress Report EHA 2023

    Report from the American Society of Clinical Oncology (ASCO) Annual Meeting (hybrid), 2nd-6th June 2023, European Hematology Association (EHA) 2023 Congress (hybrid), 8th-11th June 2023, and the 17th International Conference on Malignant Lymphoma (ICML) 2023 Congress (hybrid), 13th-17th June 2023

    Now available!


    memo – inOncology SPECIAL ISSUE

    Congress Report ASCO Lung Cancer 2023

    Report from the American Society of Clinical Oncology (ASCO) Hybrid Congress ,
    June 2nd – 6th 2023, hybrid

    Now available!

    ASH 2022 Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report ASH 2022

    Report from the American Society of Hematology (ASH) Annual Meeting,
    10th – 13th December 2022, hybrid congress

    Now available!



    All videointerviews from ASCO/EHA/ICML 2023

    Alessandra Tedeschi gives insights into the health-related quality of life data from the ASPEN study conducted in patients with Waldenström macroglobulinemia, discusses the notable results from the extended follow-up of the SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia as well as the clinical activity of zanubrutinib in the setting of R/R marginal zone lymphoma while finally depicting her personal highlights from this year’s EHA congress.

    Anna Schuh talks about genetic aberrations in subclones in terms of the molecular dynamics of relapse in patients with CLL, the benefits of liquid biopsies as well as the current role and future application of whole-genome sequencing in precision hematology while ultimately depicting her personal highlights from this year’s EHA congress.

    Paolo Strati overviews how patient outcomes can be optimized with current therapies in relapsed or refractory diffuse large B-cell lymphoma in later lines and outlines which innovative approaches might become available in the long run for the treatment of R/R DLBCL. Finally, he explains what can be achieved today in patients with follicular lymphoma and high tumor burden and depicts his personal highlights from this year’s EHA congress.

    Philipp Staber explains the role of functional drug testing in the treatment of patients with hematologic diseases, shares the rationale of the EXALT-2 trial as well as his thoughts on future developments in the field of precision medicine. Finally, he gives insights in the current research topics of the EHA SWG-Precision Hematology and their goal for the next five years.


    All videointerviews from ASCO Lung Cancer 2023

    John Heymach provides an overview on the expected benefits of HER2-selective tyrosine kinase inhibitors compared to anti-HER2-antibodies while highlighting the Beamion Lung 1 data. Moreover, he talks about RET inhibitor sensitivity and resistance in lung cancer and shares which study, presented at this year’s ASCO congress, is most likely to impact standard of care treatment in NSCLC.

    Marjorie G. Zauderer explains the correlations between histopathological features and genetics in the setting of malignant mesothelioma, and the potential benefit of studying therapeutically relevant subgroups of patients separately, critically discusses trails using PD-1 checkpoint inhibition in unresectable mesothelioma and once again encourages everyone to explore the poster sessions at the major conferences to interact with colleagues around the world.



    For Oncologists and Haematologists